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ABSTRACT 
Objective: The aim of this study was the comparison of the in vitro release performance of ibuprofen generic suspensions and reference, based on 
the hydrodynamic environment generated by the flow-through cell method (USP Apparatus 4). Results were compared with those obtained by the 
use of the USP Apparatus 2. 
Methods: The Advil® suspension (2 g/100 ml) and two generic formulations with the same dose were tested. Dissolution studies were carried out 
using a USP Apparatus 4 Sotax CE6 with 22.6 mm cells, laminar flow at 16 ml/min, and pH 7.2 phosphate buffer at 37.0±0.5 °C as dissolution 
medium. Ibuprofen was quantified spectrophotometrically at 222 nm. The in vitro release of the three drug products were studied using the USP 
Apparatus 2. The dissolution profiles of generic products were compared with the reference by model-independent, model-dependent, and analysis 
of variance (ANOVA)-based comparisons. 
Results: The dissolution profile of the generic product A was similar to the dissolution profile of reference, only with the use of the USP Apparatus 
4. The f2 similarity factor was>50 and no significant differences were found with dissolution efficiency data (*P>0.05). Similar results were found 
with the comparison of t50% and t63.2% values. Similar dissolution profiles between generic product A and reference were also found with ANOVA-
based comparisons. 
Conclusion: The flow-through cell method was adequate for study the in vitro release of ibuprofen suspensions. It is necessary to evaluate the in 
vivo performance of the drug products used in order to estimate the predictability of the proposed methodology. 
Keywords: Dissolution studies, Flow-through cell apparatus, Generic products, Ibuprofen, Suspension, USP Apparatus 4 




Ibuprofen, a poorly water-soluble non-steroidal anti-inflammatory 
drug (NSAID), is recommended for the treatment of moderate or 
acute pain. This compound is manufactured as solid oral dosage 
forms and suspensions. Ibuprofen suspension is widely used as 
antipyretic in children [1] and it is accessible for the elderly who 
cannot swallow easily [2]. Some ibuprofen formulations are 
available as generic drug products. A generic product refers to a 
bioequivalent product with the same quality and efficacy as the 
reference [3]. Generic drugs production represents savings for 
patients and hospitals and these formulations should be evaluated 
periodically. To determine whether this drug is safely 
interchangeable, the evaluation of their in vitro performance under 
conditions that simulate the natural environment of the 
gastrointestinal tract is very important. 
According to the Biopharmaceutics Classification System (BCS), 
ibuprofen is a Class II drug owing to its low solubility/high 
permeability characteristics [4]. Class II drugs are compounds with a 
dissolution-limited absorption and a significant in vitro-in vivo 
correlation (IVIVC) should be expected using a well-designed in vitro 
dissolution test. The establishment of a significant IVIVC provides 
the basis for estimating the in vivo performance of the drug and 
waives the costly bioequivalence studies [5]. Previously, some 
researchers have reported the dissolution profiles of ibuprofen 
suspension using the BCS criteria [2]. Experiments were carried out 
with the United State Pharmacopeia (USP) paddle apparatus (USP 
Apparatus 2) with 900 ml of buffer pH 7.2, pH 6.8, pH 4.5, and 0.1 M 
HCl as dissolution medium. Agitation rates of 25 and 50 rpm were 
tested. The researchers observed that the higher amount of drug 
was released at pH 7.2 (more than 100%) during 30 min and that 50 
rpm was the adequate condition to discriminate among dissolution 
profiles. Nevertheless, they only studied the reference product and 
comparisons, at the same experimental conditions, were carried out 
with the in vitro release of ibuprofen tablets. 
A dissolution test for ibuprofen suspensions, using the USP 
Apparatus 2 at 50 rpm with 900 ml of pH 7.2 phosphate buffer as the 
dissolution medium, is officially described [6]. Under these 
conditions, not less than 80% of the drug should be dissolved in 60 
min (Q ≥ 80%). This criterion is established to ensure the good 
quality of the drug products. However, previous studies have 
shown that despite most drug products meet the pharmacopeial 
dissolution criteria, some generics differed in their dissolution 
profiles when comparing with their branded counterparts, which 
questions the interchangeability between them or even among 
generic products [7]. 
The flow-through cell method (USP Apparatus 4) is an alternative 
apparatus for dissolution studies [8, 9]. Its advantages over the USP 
Apparatus 2 have been widely demonstrated, especially for the 
study of the in vitro dissolution performance of poorly water-soluble 
drugs [10, 11]. The flow-through cell method permits continuous 
extraction of the drug, simulating absorption into the systemic 
circulation, generating an intermittent flow of the dissolution 
medium into the cell where the dosage form is placed [12]. It can be 
used as an open system, allowing release under sink conditions, 
which facilitates the dissolution of poorly water-soluble drugs as 
well as change the dissolution medium within a pH range of 
physiological relevance [13]. The USP Apparatus 4 has been used to 
study the in vitro release of ibuprofen from drug products 
manufactured in immediate-release solid dosage forms [14], and in 
fixed-dose combination formulations [15]. 
Despite the advantages of the flow-through cell apparatus over 
the USP paddle apparatus, little information is available on the in 
vitro release of ibuprofen suspensions using the USP Apparatus 
4. The aim of this study was to characterize the in vitro release 
performance of ibuprofen from the reference and two generic 
formulations, using the flow-through cell method. Results 
obtained were compared with those found with the official USP 
Apparatus 2. 
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MATERIALS AND METHODS 
Products 
Ibuprofen was purchased from Sigma-Aldrich Co. (St. Louis MO, 
USA). Sodium phosphate monobasic and sodium hydroxide were 
purchased from J. T. Baker-Mexico. The Advil® suspension (Pfizer SA 
de CV, Mexico) containing ibuprofen (2 mg/100 ml), was used. The 
Mexican health authorities (COFEPRIS) have established this brand 
as reference drug product [16]. Two generic formulations containing 
the same dose were also used. The assay test was performed on all 
drug products, according to the procedures described in the USP [6]. 
The limit of related compound C, pH, and density was also 
determined. 
USP apparatus 2 
The dissolution profiles of ibuprofen from generic suspensions were 
obtained using an automated USP paddle apparatus (Sotax AT-7 
Smart, Switzerland), with a piston pump (Sotax CY7-50, 
Switzerland). A UV/Vis spectrophotometer with 1 mm flow cells 
(Perkin Elmer Lambda 35, USA) was used. All equipment and data 
generated were controlled by a specific software designed by Sotax. 
After 15 min of mechanical agitation and with a syringe, a sample of 
1 ml of suspension was added on 900 ml of pH 7.2 phosphate buffer 
at 37.0±0.5 °C. Rotational speed of 50 rpm was used. Sequential 
sampling using nitrocellulose filters (Millipore) was performed 
every 5 min until 60 min, with 12 replicates. The amount of 
ibuprofen dissolved was determined with a standard calibration 
curve at 222 nm. 
USP apparatus 4 
The dissolution profiles of ibuprofen from generic suspensions were 
obtained using an automated flow-through cell apparatus (Sotax 
CE6, Switzerland), with 22.6-mm cells (i.d.) and a piston pump 
(Sotax CY7−50, Switzerland). A UV/Vis spectrophotometer with 1 
mm flow cells (Perkin Elmer Lambda 10, USA) was used. In all 
experiments, laminar flow (with a bed of 6 g of glass beads) was 
used. Deareated pH 7.2 phosphate buffer at 37.0±0.5 °C was pumped 
at 16 ml/min. An open system was used, without recycling the 
dissolution medium. After 15 min of mechanical agitation and with a 
syringe, a sample of 1 ml of suspension was added into each cell. 
Sequential sampling using nitrocellulose filters (Millipore) was 
performed every 5 min until 60 min, with 12 replicates. The amount 
of ibuprofen dissolved was determined with a standard calibration 
curve at 222 nm. 
Data analysis 
The dissolution profiles of the generic drug products A and B vs. 
reference were compared by model-independent,-dependent and 
analysis of variance (ANOVA)-based methods [12, 17]. For model-
independent comparisons, the f2 similarity factor, mean dissolution 
time (MDT), and dissolution efficiency (DE) were calculated. 
Furthermore, the percentage of ibuprofen dissolved at 60 min was 
also compared. The parameters of generic products A and B vs. 
reference were compared using a univariate one-way ANOVA 
followed by a Dunnett’s multiple comparison tests. Differences were 
considered significant if *P<0.05. For calculation of DE and MDT 
values, the Excel add-in DDSolver was used [18]. For all statistical 
comparisons, SigmaPlot software was used (version 11.0). 
For model-dependent comparisons, dissolution data were fitted to 
Weibull, logistic, Gompertz, and probit models. The model with the 
highest adjusted determination coefficient (R2adjusted) and the 
minimum Akaike information criterion (AIC) was chosen as the best 
fit model [17]. Data analysis was performed using the Excel add-in 
DDSolver. Additionally, dissolution data were fitted to sigmoidal 
model using SigmaPlot software. With this fit, the t50% and t63.2% 
values were calculated. The values of the generic products A and B 
vs. reference were statistically compared and differences were 
considered significant if *P<0.05. 
The ANOVA-based comparisons were carried out with the 
percentage of ibuprofen dissolved at each time point using a 
univariate one-way ANOVA followed by a Dunnett’s multiple 
comparisons test. Differences were considered significant if *P<0.05. 
RESULTS AND DISCUSSION 
All drug products met the assay test specified in the USP. The 
percentages of ibuprofen were between 90 and 110% [6]. The limit 
of related compound C, pH, and density data are shown in table 1.
 
Table 1: Characterization of ibuprofen suspensions 
Code Assay (%), RSD (%) Limit of related compound C (%) pH Density (g/ml) 
R 100.8, 0.73 0 4.138 1.2491 
A 97.6, 0.21 0 5.366 1.1702 
B 99.9, 1.27 0 4.133 1.1729 
RSD: relative standard deviation 
 
Dissolution profiles 
The dissolution profiles of ibuprofen suspensions are shown in fig. 1. 
Considering a single-point specification (Q ≥ 80% in 60 min), all 
drug products met the pharmacopeial dissolution criterion using 
both dissolution apparatuses. It is important to note that the generic 
product B released the complete dose of ibuprofen at the first 
sampling time (5 min) when using the USP Apparatus 2. 
 
 
Fig. 1: Dissolution profiles of ibuprofen suspensions, R) reference and A) and B) generic products. mean±SD, n = 12 
Medina et al. 
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Although all drug products met the pharmacopeial dissolution 
criterion, differences in dissolution profiles of both generic products 
vs. reference were found. The f2 similarity factor of the generic 
products A and B, were 49.48 and 37.98 respectively when using the 
USP paddle apparatus. In the same order, the f2 values were 63.46 
and 40.85, when using the flow-through cell method. With these 
results, the dissolution profile of the generic product A, was 
considered similar to the dissolution profile of reference (f2>50), 
only when using the USP Apparatus 4. 
All drug products showed slightly slow in vitro release of ibuprofen 
when using the flow-through cell apparatus (>35% dissolved in 5 
min vs.>50% at the same time with the USP paddle apparatus). Some 
researchers have suggested that this result can be explained by the 
hydrodynamic conditions that characterize the USP Apparatus 4, 
which lacks an agitation mechanism, and by the fact that the dosage 
form and the drug particles are continuously exposed to uniform 
laminar flow, similar to the natural environment of the gastro-
intestinal tract, causing different dissolution pattern [19]. When 
using the flow-through cell apparatus, cell size, glass beads, and flow 
rate are critical factors in determining the dissolution pattern. The 
flow rate of 16 ml/min is suggested by the European and USP [20]. 
When the flow rate of the dissolution medium is 16 ml/min, the fluid 
flow inside the 22.6-mm cells is 4 cm/min [21]. Fotaki et al. [21] 
reported that the axial velocity of the intestinal fluid is 
approximately 1.5 cm/min. Therefore, the axial velocity of 4 cm/min 
generated under the experimental conditions described above is 
close to reported physiological parameters. 
Model-independent comparisons 
The mean values±standard error of the mean (SEM) of ibuprofen 
dissolved at 60 min, and model-independent parameters MDT and 
DE, are shown in table 2. In all comparisons, significant differences 
were observed between the dissolution profiles of the generic 
products A and B vs. reference (*P<0.05), excepting the DE value of 
the generic product A, with the USP Apparatus 4 (*P>0.05). 
 
Table 2: Model-independent parameters of ibuprofen suspensions 
USP Code % Diss. at 60 min MDT (min) DE (%) 
2 R 101.97±2.30 6.81±0.17 90.35±1.88 
A 91.33±1.23* 4.14±0.16* 85.01±1.08* 
B 108.58±0.84* 3.36±0.10* 102.49±0.75* 
4 R 103.77±1.55 5.28±0.21 94.67±1.63 
A 111.08±2.75* 6.86±0.22* 98.33±2.31 
B 88.90±1.96* 6.12±0.25* 79.79±1.61* 
R: reference, A and B: generic products, MDT: mean dissolution time, DE: dissolution efficiency. mean±SEM, n = 12, *P<0.05 
 
The model-independent parameters MDT and DE are commonly 
used parameters to compare dissolution profiles. The MDT 
represents the average time at which 63.2% of the dose is 
dissolved, and DE relates the area under the curve of the 
dissolution profile to the total area of the rectangle formed, by the 
theoretical dissolution of 100% of the dose and the time interval of 
the test. The MDT and DE have been also proposed as satisfactory 
parameters for in vitro-in vivo correlation (IVIVC) levels B and C 
[22]. Level B is defined as the relationship between the MDT and 
mean residence time (average time that a molecule stays in the 
body), and both parameters are calculated by statistical moments 
analysis. Level C is defined as the association between a 
dissolution time point (t50%, t85%, etc.) and one pharmacokinetic 
parameter, such as area under the curve, Cmax, or Tmax. The DE 
value is used by some researchers as an appropriate parameter to 
expresses the global drug dissolution performance, useful for 
comparison of dissolution profiles [23] or to relate it to some in 
vivo parameter. 
Model-dependent comparisons 
The R2 adjusted and AIC mean values for ibuprofen suspensions are 
shown in table 3. 
 
Table 3: Criteria used for the selection of the best fit model 
 USP Apparatus 2 USP Apparatus 4 
Code Weibull logistic Gompertz probit Weibull logistic Gompertz probit 
R2adjusted 
R 0.9888 0.9773 0.9722 0.9813 0.9968 0.9951 0.9939 0.9965 
A 0.9968 0.9973 0.9974 0.9970 0.9969 0.9991 0.9976 0.9996 
B 0.9460 0.9453 0.9452 0.9450 0.9901 0.9817 0.9774 0.9850 
AIC 
R 33.33 47.04 50.16 43.21 28.71 33.85 37.22 29.26 
A 0.06 -2.12 -2.38 -0.61 33.26 19.16 30.92 7.74 
B -5.56 -5.49 -5.46 -5.29 27.12 33.20 37.18 29.13 
R: reference, A and B: generic products, AIC: Akaike information criterion. Mean, n = 12 
 
The dissolution data of the reference and generic product B, were 
well fitted to the Weibull function when using USP Apparatus 2 and 
4. Both products reached the highest values of R2adjusted and the 
lowest values of AIC. The dissolution data for the generic product A 
were well fitted to the Gompertz function and probit equation, when 
using the USP Apparatus 2 and 4, respectively. None of the ibuprofen 
data was well fitted by the logistic model. 
The Weibull function (Eq. 1) is widely used for the study of in vitro 
drug release mechanisms [24]. An advantage of this model is that 
parameter calculation is independent of whether or not sink 
conditions prevail [25]. As the generic product B and reference were 
well adjusted to this function, β parameter was used to compare the 
dissolution profiles. Mean data were compared by a Student’s t-test 
and significant differences were found (*P<0.05). The dissolution 
profiles of generic product B were considered dissimilar respect to 
the dissolution profile of reference, in both dissolution apparatuses. 
 Eq. [1] 
Where α is the scale parameter and β is the shape parameter [18]. 
Because all drug products showed adequate R2adjusted values, the 
Weibull parameters of the three formulations were calculated, and 
parameters and Td values are shown in table 4. 
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Table 4: Model-dependent parameters (Weibull function) and Td values 
USP Code α β Fmax Td (±SEM) 
2 R 8.16 1.08 102.19 6.81±0.22 
A 12.09 1.69 90.83 4.11±0.15 
B 0.47 0.08* 114.01 † 
4 R 61.55 2.15 105.11 6.79±0.15 
A 43.18 1.84 111.09 7.70±0.20 
B 49.82 1.87* 89.58 7.27±0.25 
α: scale parameter, β: shape parameter. Mean, n = 12, *P<0.05, † no real value was found 
 
As in vitro release of ibuprofen from the generic product, B was fast, 
using the USP paddle apparatus (the complete dose was dissolved at 5 
min), no real value for the Td parameter was found. The Td parameter 
is equivalent to the model-independent parameter MDT [26]. 
The Weibull shape parameter β characterizes the dissolution profile 
as exponential (β = 1); as sigmoid S-shaped, with upward curvature 
followed by a turning point (β>1); or as parabolic, with a steeper 
initial slope that is consistent with the exponential (β<1) [26]. The in 
vitro release of ibuprofen from the three drug products showed β 
values>1, meaning sigmoidal profiles excepting the generic product 
B under the hydrodynamic environment of USP Apparatus 2. By the 
obtained results, the in vitro release of ibuprofen from suspensions 
seems not to be the same in the USP Apparatus 2 and 4. To confirm 
this result, the MDT and Td values were separately plotted by 
dissolution apparatus. Results are shown in fig. 2. 
 
 
Fig. 2: Linear regression between Td vs. MDT values of ibuprofen from the generic products A and B and reference (R) Mean, n = 12 
 
Only linear regression of data obtained with the USP Apparatus 4 
was significant (*P<0.05). This results confirm that the in vitro 
release of ibuprofen suspensions, under the hydrodynamic 
environment generated by the USP Apparatus 4, is better than that 
generated by the USP paddle apparatus, independently of the used 
formulation. These results agree with previous reports of in vitro 
studies of ibuprofen in fixed-dose combination formulations [15]. 
Because an inconsistent fitting was found when using the 
mathematical models described above, and with almost all drug 
products the β values were>1, the sigmoidal model (Eq. 2) was used 
to fit the dissolution data. 
 Eq. [2] 
Where a, b and x0 are constants [18]. 
The data adjusted to the sigmoidal model allowed to obtain R2 values 
higher than 0.99, excepting the R2 value of the generic product B 
(>0.98). With a, b, and x0 parameters, the t50% and t63.2% values were 
calculated. Data of sigmoidal model parameters and tx% values are 
shown in table 5. 
 
Table 5: Model-dependent parameters (Sigmoidal equation) and tx% values 
USP Code R2 a b x0 t50% (min) t63.2% (min) 
2 R 0.9954 101.94 4.54 4.62 4.45 6.88 
A 0.9974 90.83 1.49 3.35 3.65* 4.58* 
B 0.9843 109.62 35.23 -98.07 † † 
4 R 0.9973 105.14 1.92 5.74 5.59 6.58 
A 0.9973 111.04 2.51 6.41 5.92 7.14 
B 0.9937 89.61 2.56 5.99 6.56* 8.21* 
Mean, n = 12, *P<0.05, † no real values were found 
 
As the in vitro release of ibuprofen from the generic product B was 
fast, when using the USP Apparatus 2, no real value for the t50% and 
t63.2% parameters were calculated. Dissolution profiles were 
compared with the tx% values and significant differences were found 
(*P<0.05) between the generic product A vs. reference (USP 
Apparatus 2, Student’s t-test), and between the generic product B vs. 
reference (USP Apparatus 4, univariate one-way ANOVA). 
The tx% and sampling time values are commonly used to 
characterize the drug release rate. The tx% value corresponds to 
the time necessary to release a determined percentage of drug (e. 
g., t10%, t50%, t90%) and the sampling time corresponds to the amount 
of drug dissolved in that time (e. g., t10 min, t50 min, t90 min). 
Pharmacopeias use this parameter as an acceptable limit for the 
dissolution test (e. g., t45 min ≥ 80%) [27]. 
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ANOVA-based comparisons were used to compare the dissolution 
profiles of the ibuprofen suspensions. The advantage of this 
approach is that it is not restricted to any of the requirements of 
model-independent comparisons. Additionally, it does not depend 
on data fitting to a specific equation. Comparisons between the 
generic products A and B vs. reference, when using both dissolution 
apparatuses, were carried out at each sampling time. Results are 
shown in table 6. 
 
Table 6: Dunnett’s multiple comparison tests for the percentage of ibuprofen dissolved at each time point of the generic product A and B 
vs. reference 
Comparison Time (min) USP Apparatus 2 USP Apparatus 4 
Difference *P Difference *P 
A vs. R 5 14.31 <0.05 2.89 >0.05 
10 12.28 <0.05 3.92 >0.05 
15 1.57 >0.05 0.11 >0.05 
20 8.80 <0.05 3.37 >0.05 
25 5.60 <0.05 4.96 >0.05 
30 10.64 <0.05 5.67 >0.05 
35 10.73 <0.05 6.06 >0.05 
40 10.73 <0.05 6.36 >0.05 
45 10.72 <0.05 6.61 >0.05 
50 10.75 <0.05 6.83 >0.05 
55 10.72 <0.05 7.06 <0.05 
60 10.63 <0.05 7.30 <0.05 
B vs. R 5 50.79 <0.05 6.69 <0.05 
10 28.14 <0.05 21.66 <0.05 
15 14.09 <0.05 16.82 <0.05 
20 7.16 <0.05 16.74 <0.05 
25 10.59 <0.05 16.39 <0.05 
30 5.81 <0.05 16.00 <0.05 
35 5.85 <0.05 15.74 <0.05 
40 6.04 <0.05 15.54 <0.05 
45 6.20 <0.05 15.36 <0.05 
50 6.27 <0.05 15.20 <0.05 
55 6.39 <0.05 15.03 <0.05 
60 6.61 <0.05 14.87 <0.05 
 
Significant differences were found (*P<0.05) at most time points 
excepting, the generic product A vs. reference until 50 min. when using 
the flow-through cell apparatus. The statistical analysis emphasized 
the great sensitivity and discriminative capacity of the flow-through 
cell apparatus in the evaluation of the in vitro release of ibuprofen 
suspensions in comparison to the official USP paddle apparatus. 
After the application of the three methods to compare the 
dissolution profiles of two generic products of ibuprofen 
suspensions against the reference it can be observed that with the 
use of the USP Apparatus 2, the dissolution profiles of the generic 
products A and B were dissimilar, however, with the flow-through 
cell apparatus only the generic product B had dissimilar dissolution 
profile. The relationship of these differences with the in vivo 
performance has not been demonstrated yet. Because little 
information is available on ibuprofen suspensions under the 
hydrodynamic environment generated by the USP Apparatus 2 and 
4, additional research is necessary. Some authors have suggested the 
optimization of the flow-through cell to obtain reliable and 
discriminative results reflecting the formulation variables prior to 
bioequivalence testing [12]; as well as the in vivo bioequivalence 
studies for generic and brand drugs are required to be conducted to 
ascertain more precise therapeutic and clinical equivalence [28]. 
Finally, it is important to emphasize that this is the first in vitro 
release study of ibuprofen generic suspensions comparing the flow-
through cell method and the official USP paddle apparatus. The 
clinical impact of the results here obtained should be evaluated 
using appropriate clinical protocols. 
CONCLUSION 
Characterization of the in vitro release of ibuprofen suspensions using 
the flow-through cell apparatus revealed similarities in the dissolution 
rate of the generic formulation A and the reference product. Given the 
physicochemical characteristics of ibuprofen and the environment in 
which the formulations were tested, the differences found with the 
generic formulation B could be of clinical relevance. 
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